Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies von Siegel, David, Martin, Thomas, Nooka, Ajay, Harvey, R Donald, Vij, Ravi, Niesvizky, Ruben, Badros, Ashraf Z, Jagannath, Sundar, McCulloch, Leanne, Rajangam, Kanya, Lonial, Sagar

Volltext

Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease von Choi, Jaebok, Cooper, Matthew L., Staser, Karl, Ashami, Kidist, Vij, Kiran R., Wang, Bing, Marsala, Lynne, Niswonger, Jessica, Ritchey, Julie, Alahmari, Bader, Achilefu, Samuel, Tsunoda, Ikuo, Schroeder, Mark A., DiPersio, John F.

Volltext

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time von Kumar, S K, Dispenzieri, A, Fraser, R, Mingwei, F, Akpek, G, Cornell, R, Kharfan-Dabaja, M, Freytes, C, Hashmi, S, Hildebrandt, G, Holmberg, L, Kyle, R, Lazarus, H, Lee, C, Mikhael, J, Nishihori, T, Tay, J, Usmani, S, Vesole, D, Vij, R, Wirk, B, Krishnan, A, Gasparetto, C, Mark, T, Nieto, Y, Hari, P, D'Souza, A

Volltext

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety von Badros, A Z, Vij, R, Martin, T, Zonder, J A, Kunkel, L, Wang, Z, Lee, S, Wong, A F, Niesvizky, R

Volltext

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects von Hurchla, M A, Garcia-Gomez, A, Hornick, M C, Ocio, E M, Li, A, Blanco, J F, Collins, L, Kirk, C J, Piwnica-Worms, D, Vij, R, Tomasson, M H, Pandiella, A, San Miguel, J F, Garayoa, M, Weilbaecher, K N

Volltext

Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML von Rashidi, A, Slade, M, DiPersio, J F, Westervelt, P, Vij, R, Romee, R

Volltext

PHARMACIST ATTITUDES TOWARDS ADMINISTRATION OF DEPOT-MEDROXYPROGESTERONE ACETATE FOR CONTRACEPTION IN THE OUTPATIENT SETTING von Ellenberg, K, Vij, R

Volltext

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study von Jakubowiak, A J, Siegel, D S, Martin, T, Wang, M, Vij, R, Lonial, S, Trudel, S, Kukreti, V, Bahlis, N, Alsina, M, Chanan-Khan, A, Buadi, F, Reu, F J, Somlo, G, Zonder, J, Song, K, Stewart, A K, Stadtmauer, E, Harrison, B L, Wong, A F, Orlowski, R Z, Jagannath, S

Volltext

High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma von Wildes, T M, Finney, J D, Fiala, M, Gao, F, Vij, R, Stockerl-Goldstein, K, Carson, K R, Mikhael, J, Colditz, G

Volltext

Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation? von Rashidi, A, DiPersio, J F, Westervelt, P, Vij, R, Abboud, C N, Romee, R

Volltext

A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML von Ramsingh, G, Westervelt, P, Cashen, A F, Uy, G L, Stockerl-Goldstein, K, Abboud, C N, Bernabe, N, Monahan, R, DiPersio, J F, Vij, R

Volltext

Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation von Huselton, E, Slade, M, DiPersio, J F, Westervelt, P, Vij, R, Uy, G L, Fehniger, T A, Abboud, C N, Gao, F, Schroeder, M A, Romee, R

Volltext

Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity von Liu, Xiuting, Hogg, Graham D., Zuo, Chong, Borcherding, Nicholas C., Baer, John M., Lander, Varintra E., Kang, Liang-I, Knolhoff, Brett L., Ahmad, Faiz, Osterhout, Robin E., Galkin, Anna V., Bruey, Jean-Marie, Carter, Laura L., Mpoy, Cedric, Vij, Kiran R., Fields, Ryan C., Schwarz, Julie K., Park, Haeseong, Gupta, Vineet, DeNardo, David G.

Volltext

PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB‐CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPL... von Vij, R., Schade, H., Trudel, S., Chang, A. C., Huang, J., Samineni, D., Sumiyoshi, T., Tsai, J., Wong, T., Harrison, S. J.

Volltext

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE‐CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA‐3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL... von Rodríguez‐Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A.K., Manier, S., Callander, N., Costa, L.J., Vij, R., Bahlis, N.J., Moreau, P., Solomon, S.R., Delforge, M., Berdeja, J., Truppel‐Hartmann, A., Yang, Z., Favre‐Kontula, L., Wu, F., Piasecki, J., Cook, M., Giralt, S.

Volltext

Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable... von Bhamidipati, P K, DiPersio, J F, Stokerl-Goldstein, K, Rashidi, A, Gao, F, Uy, G L, Westervelt, P, Vij, R, Schroeder, M A, Abboud, C N, Keller, J W, Fehniger, T A, Romee, R

Volltext

P963: EVOLUTION OF TREATMENT PATTERNS AND OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING A SECOND LINE OF THERAPY BETWEEN 2012 AND 2020: ANALYSIS... von Kuter, D., Goldschmidt, H., Cella, D., Petrucci, M. T., Moreau, P., Durie, B., Juarez‐Garcia, A., Trong, L., Gu, J., Hernandez Rivera, G., Dhanasiri, S., Marshall, T., Wang, J., Lacoin, L., Ramasamy, K., Vij, R.

Volltext

Odontogenic keratocyst: a peripheral variant von Vij, H, Vij, R, Gupta, V, Sengupta, S

Volltext

P958: REAL‐LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY von Einsele, H., Moreau, P., De Stefano, V., Dytfeld, D., Angelucci, E., Benjamin, R., Goldschmidt, H., Donk, N. W., Besemer, B., Scheid, C., Vij, R., ’. Groen‐Damen, E. I., Semerjian, M., Strulev, V., Schecter, J. M., Roccia, T., Nesheiwat, T., Wapenaar, R., Weisel, K., Mateos, M.‐V.

Volltext

A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use von Jonsson, F, Ou, Y, Claret, L, Siegel, D, Jagannath, S, Vij, R, Badros, A, Aggarwal, S, Bruno, R

Volltext